Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response
0
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Few studies have investigated prognostic factors for the development of liver-related events (LREs) in patients with chronic hepatitis C (CHC) who achieve sustained virological response (SVR). Methods: We analyzed 190 patients with CHC who achieved SVR after treatment with pegylated interferon (peg-IFN) plus ribavirin. LREs were defined as any complications related to cirrhosis, hepatocellular carcinoma (HCC), or liver-related mortality. Results: The mean age was 54.1 years, and 84 of the patients (44.2%) were male. The mean liver stiffness (LS) value at SVR was 7.1±5.4 kPa. During the follow-up period (median, 43.0 months), LREs occurred in 10 patients (5.3%; HCC in eight patients, ascites in one patient, and liver-related mortality in one patient). By multivariate Cox regression analysis, age, α-fetoprotein level, and LS value were independent predictors for LRE development (all p<0.05). Patients with LS values ≥7.0 kPa had a greater risk (hazard ratio, 9.472; 95% confidence interval, 1.018 to 88.126; p=0.048) for LRE development compared to those with LS values <7.0 kPa. Conclusions: The LS value at SVR is useful for predicting LRE development in CHC patients who achieve SVR after treatment with peg-IFN plus ribavirin. Thus, LRE surveillance strategies might be optimized according to the LS values at SVR, even with complete viral eradication.
Abstract
Background/Aims: Few studies have investigated prognostic factors for the development of liver-related events (LREs) in patients with chronic hepatitis C (CHC) who achieve sustained virological response (SVR). Methods: We analyzed 190 patients with CHC who achieved SVR after treatment with pegylated interferon (peg-IFN) plus ribavirin. LREs were defined as any complications related to cirrhosis, hepatocellular carcinoma (HCC), or liver-related mortality. Results: The mean age was 54.1 years, and 84 of the patients (44.2%) were male. The mean liver stiffness (LS) value at SVR was 7.1±5.4 kPa. During the follow-up period (median, 43.0 months), LREs occurred in 10 patients (5.3%; HCC in eight patients, ascites in one patient, and liver-related mortality in one patient). By multivariate Cox regression analysis, age, α-fetoprotein level, and LS value were independent predictors for LRE development (all p<0.05). Patients with LS values ≥7.0 kPa had a greater risk (hazard ratio, 9.472; 95% confidence interval, 1.018 to 88.126; p=0.048) for LRE development compared to those with LS values <7.0 kPa. Conclusions: The LS value at SVR is useful for predicting LRE development in CHC patients who achieve SVR after treatment with peg-IFN plus ribavirin. Thus, LRE surveillance strategies might be optimized according to the LS values at SVR, even with complete viral eradication.
참고문헌 (26)
- Morisco F, "Sustained virological response:a milestone in the treatment of chronic hepatitis C", World J Gastroenterol, 19, pp.2793~2798 (2013)
- Bruno S, "Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis: a 12-year prospective follow-up study", Hepatology, 51, pp.2069~2076 (2010)
- Fernández-Rodríguez CM, "Peginterferon plus ribavirin and sustained virological response in HCVrelated cirrhosis: outcomes and factors predicting response", Am J Gastroenterol, 105, pp.2164~2172 (2010)
- Bruno S, "Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study", Hepatology, 45, pp.579~587 (2007)
- Aleman S, "A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis", Clin Infect Dis, 57, pp.230~236 (2013)
- Morgan TR, "Outcome of sustained virological responders with histologically advanced chronic hepatitis C", Hepatology, 52, pp.833~844 (2010)
- Masuzaki R, "Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis", liver cirrhosis, 2010, pp.78(1), 17~23
- Masuzaki R, "Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography", Hepatology, 49, pp.1954~1961 (2009)
- Toccaceli F, "Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon", J Viral Hepat, 10, pp.126~133 (2003)
- Mallet V, "Brief communication:the relationship of regression of cirrhosis to outcome in chronic hepatitis C", Ann Intern Med, 149, pp.399~403 (2008)
- Castera L, "How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?", Liver Int, 31(1), pp.13~17 (2011)
- Amorim TG, "Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C", Ann Hepatol, 11, pp.855~861 (2012)
- Tsochatzis EA, "Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy", J Hepatol, 54, pp.650~659 (2011)
- Poynard T, "Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTestTM) and transient elastography (FibroScanⓇ)", J Hepatol, 60, pp.706~714 (2014)
- Sandrin L, "Transient elastography:a new noninvasive method for assessment of hepatic fibrosis", Ultrasound Med Biol, 29, pp.1705~1713 (2003)
- Castera L, "Noninvasive methods to assess liver disease in patients with hepatitis B or C", Gastroenterology, 142(e4), pp.1293~1302 (2012)
- D’Ambrosio R, "The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response", J Hepatol, 59, pp.251~256 (2013)
- Chon YE, "The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B", J Clin Gastroenterol, 46, pp.518~525 (2012)
- Jung KS, "Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan)", Hepatology, 53, pp.885~894 (2011)
- European Association for Study of Liver, "EASL Clinical Practice Guidelines: management of hepatitis C virus infection", J Hepatol, 60, pp.392~420 (2014)
- Asahina Y, "Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection", Hepatology, 52, pp.518~527 (2010)
- Oze T, "Post-treatment levels of alpha-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy", Clin Gastroenterol Hepatol, 12, pp.1186~1195 (2014)
- Zois CD, "Systematic review: hepatic fibrosis: regression with therapy", Aliment Pharmacol Ther, 28, pp.1175~1187 (2008)
- Asahina Y, "Alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C", Hepatology, 58, pp.1253~1262 (2013)
- Bari K, "Combination of daclatasvir and sofosbuvir for hepatitis C genotypes 1, 2, and 3", Gastroenterology, 147, pp.534~536 (2014)
- Lawitz E, "Sofosbuvir for previously untreated chronic hepatitis C infection", N Engl J Med, 368, pp.1878~1887 (2013)